A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Conditions:   Chronic Obstructive Pulmonary Disease;   Lung Non-Small Cell Carcinoma;   Pneumonia;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8 Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials